Franklin Resources Inc. boosted its position in shares of CRISPR Therapeutics (NASDAQ:CRSP) by 8.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 794,533 shares of the company’s stock after acquiring an additional 65,200 shares during the period. Franklin Resources Inc. owned 1.73% of CRISPR Therapeutics worth $18,656,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. Artal Group S.A. purchased a new position in CRISPR Therapeutics during the fourth quarter valued at approximately $1,174,000. JPMorgan Chase & Co. bought a new stake in CRISPR Therapeutics during the third quarter valued at approximately $536,000. Wells Fargo & Company MN lifted its position in CRISPR Therapeutics by 129.8% during the third quarter. Wells Fargo & Company MN now owns 18,352 shares of the company’s stock valued at $328,000 after purchasing an additional 10,365 shares during the last quarter. D.A. Davidson & CO. bought a new stake in CRISPR Therapeutics during the fourth quarter valued at approximately $370,000. Finally, Aevitas Wealth Management Inc. bought a new stake in CRISPR Therapeutics during the fourth quarter valued at approximately $671,000. 26.50% of the stock is owned by institutional investors.
Shares of NASDAQ CRSP traded down $0.79 during mid-day trading on Friday, hitting $51.77. The stock had a trading volume of 843,108 shares, compared to its average volume of 1,077,869. The company has a market cap of $2,479.09, a price-to-earnings ratio of -30.27 and a beta of 3.56. CRISPR Therapeutics has a 1 year low of $13.50 and a 1 year high of $61.24.
Several equities research analysts have issued reports on the stock. Zacks Investment Research lowered shares of CRISPR Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 25th. Piper Jaffray reiterated an “overweight” rating and set a $53.70 target price (down from $67.00) on shares of CRISPR Therapeutics in a research report on Friday, March 9th. Oppenheimer reiterated a “hold” rating on shares of CRISPR Therapeutics in a research report on Thursday, December 21st. Barclays boosted their price objective on shares of CRISPR Therapeutics from $29.00 to $59.00 and gave the stock an “overweight” rating in a report on Wednesday, March 7th. Finally, Goldman Sachs began coverage on shares of CRISPR Therapeutics in a report on Friday, April 6th. They issued a “buy” rating and a $86.00 price objective for the company. Five investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $63.95.
In other CRISPR Therapeutics news, insider Tyler Dylan-Hyde sold 66,000 shares of the business’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $28.03, for a total transaction of $1,849,980.00. Following the transaction, the insider now directly owns 25,204 shares of the company’s stock, valued at approximately $706,468.12. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 39.98% of the stock is currently owned by insiders.
CRISPR Therapeutics Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
Receive News & Ratings for CRISPR Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CRISPR Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.